Scarica l'app Stockscreener
220.22
4.05%
8.58
Pre-mercato:
219.26
-0.96
-0.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$211.64
Aprire:
$220.35
Volume 24 ore:
7.65M
Relative Volume:
1.42
Capitalizzazione di mercato:
$389.03B
Reddito:
$58.33B
Utile/perdita netta:
$3.73B
Rapporto P/E:
104.87
EPS:
2.1
Flusso di cassa netto:
$18.24B
1 W Prestazione:
+3.39%
1M Prestazione:
+10.86%
6M Prestazione:
+3.10%
1 anno Prestazione:
+13.17%
Intervallo 1D:
$216.75
$221.76
Intervallo di 1 settimana:
$207.61
$221.76
Portata 52W:
$163.81
$221.76
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Confronta ABBV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
220.22 | 373.87B | 58.33B | 3.73B | 18.24B | 2.10 |
|
LLY
Lilly Eli Co
|
756.28 | 676.48B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.50 | 423.36B | 90.62B | 22.66B | 18.18B | 9.35 |
|
NVS
Novartis Ag Adr
|
127.70 | 244.98B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
85.15 | 209.89B | 63.43B | 16.42B | 14.72B | 6.49 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-12 | Ripresa | Piper Sandler | Overweight |
| 2025-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie extends Rinvoq exclusivity by four years after generics settlements - Yahoo Finance
Intrua Financial LLC Sells 1,688 Shares of AbbVie Inc. $ABBV - MarketBeat
Strs Ohio Invests $158.73 Million in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV is Advisors Capital Management LLC's 4th Largest Position - MarketBeat
Wells Fargo Adjusts Price Target on AbbVie to $260 From $240, Maintains Overweight Rating - MarketScreener
AbbVie settles Rinvoq patent disputes, pushing back generics to 2037 - The Pharma Letter
Acadian Asset Management LLC Has $29.90 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
Meet the Vanguard ETF That Yields More Than Twice the S&P 500 Average and Has Minimal Fees - The Motley Fool
Competitiveness Wins if IRS Accepts Tax Court Ruling in AbbVie - Bloomberg Law News
Dynamic Technology Lab Private Ltd Invests $383,000 in AbbVie Inc. $ABBV - MarketBeat
Meiji Yasuda Asset Management Co Ltd. Sells 31,981 Shares of AbbVie Inc. $ABBV - MarketBeat
Hamilton Capital LLC Sells 1,209 Shares of AbbVie Inc. $ABBV - MarketBeat
Peloton Wealth Strategists Sells 7,000 Shares of AbbVie Inc. $ABBV - MarketBeat
RNC Capital Management LLC Sells 3,361 Shares of AbbVie Inc. $ABBV - MarketBeat
Coppell Advisory Solutions LLC Acquires 1,244 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Logs Best Day In Over 7 Months As Wall Street Cheers Rinvoq Patent Deal Pushing Generics To 2037 - Stocktwits
AbbVie (NYSE:ABBV) Trading Down 1%What's Next? - MarketBeat
AbbVie Stock Breaks Out As Its Cash Cow Lives To Fight Another Day - Investor's Business Daily
AbbVie shares hit record high as key immunology drug set for exclusivity until 2037 - Reuters
AbbVie Stock Touches Record High After Company Dismisses Generic Competition For Rinvoq Till 2037: Wells Fargo Terms It A ‘Big Win’ - Stocktwits
One of AbbVie's key drugs gains protection from generic competition for more than a decade - Crain's Chicago Business
AbbVie shares rise with extension of RINVOQ patent protection to 2037 - Proactive financial news
AbbVie in Settlement With Generic Drugmakers on Rinvoq - The Wall Street Journal
Why AbbVie (ABBV) Stock Is Trading Up Today - FinancialContent
Why AbbVie Stock Is Jumping Today - Yahoo Finance
AbbVie lifted by lengthy delay to generics of Rinvoq - pharmaphorum
AbbVie’s Rinvoq Franchise Secures Extended Exclusivity, Boosting Long-Term Prospects and Justifying Buy Rating - TipRanks
‘Really Long Runway’: AbbVie Stock (ABBV) Jumps afer Settlement on Anti-Inflammatory Drug - TipRanks
Market movers: Opendoor, Centene, Delta, AbbVie, Sandisk... - Proactive financial news
AbbVie stock rises after securing patent protection for RINVOQ until 2037 - Investing.com Canada
AbbVie Inc. $ABBV Shares Sold by McAdam LLC - MarketBeat
AbbVie stock reaches all-time high at 220.84 USD - Investing.com India
Wells sees AbbVie Rinvoq settlement being worth $11-$24 per share - TipRanks
Blue Rock Wealth Management LLC Makes New $285,000 Investment in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
AbbVie Inc. $ABBV Shares Sold by Fortis Capital Advisors LLC - MarketBeat
AbbVie Inc. $ABBV Stock Position Lowered by Belpointe Asset Management LLC - MarketBeat
Focus Partners Wealth Raises Position in AbbVie Inc. $ABBV - MarketBeat
Intech Investment Management LLC Lowers Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Bought by Integrity Alliance LLC. - MarketBeat
Glenview Trust co Grows Position in AbbVie Inc. $ABBV - MarketBeat
Anchor Investment Management LLC Decreases Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie settles with generic drugmakers for key immunology drug Rinvoq - Seeking Alpha
Ransom Advisory Ltd Buys Shares of 13,215 AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Plato Investment Management Ltd - MarketBeat
AbbVie Inc settles litigation with generic manufacturers for RinvoqSEC filing - MarketScreener
SCS Capital Management LLC Buys Shares of 17,600 AbbVie Inc. $ABBV - MarketBeat
1,501 Shares in AbbVie Inc. $ABBV Acquired by MBB Public Markets I LLC - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 54,966 Shares of AbbVie Inc. $ABBV - MarketBeat
Pacific Center for Financial Services Sells 1,601 Shares of AbbVie Inc. $ABBV - MarketBeat
Cinctive Capital Management LP Makes New $741,000 Investment in AbbVie Inc. $ABBV - MarketBeat
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
0.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):